Regeneron Pharmaceuticals (REGN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$827.72-1.87%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · REGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 9.5% |
| Our one-year growth estimate | diamond | 14.4% |
Growth built into the price is above our model estimate.
The price assumes 4.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers
Review the full earnings evidenceWhy it matters: Stable EYLEA HD sales would show recovery from competition. This would support revenue.
Watch forEYLEA HD U.S. net sales stabilize or grow in Q3 after a strong Q2.
Also watch forEYLEA HD U.S. net sales decline further in Q3.
Why it matters: A good FDA decision would show Regeneron's gene therapy can work. It would help investors feel more confident.
Supportive ifFDA approval of the BLA for DB-OTO (gene therapy for hearing loss) expected in the first half of 2026.
Worry ifFDA rejects the BLA for DB-OTO or delays the decision beyond the expected timeline.
Why it matters: Keeping gross margin guidance shows the company can control costs. This is important for making money.
Supportive ifManagement says GAAP gross margin guidance is the same or better.
Worry ifManagement lowers GAAP gross margin guidance below where it is now.
Why it matters: Good results could help Regeneron's plans. This may attract more investors to its oncology portfolio.
Watch forPhase 3 results show a big gain in progression-free survival. This is better than pembrolizumab.
Also watch forPhase 3 results do not show a big improvement in progression-free survival.
Why it matters: Dupixent sales are a major revenue driver. Slower growth may signal market challenges.
Worry ifQ3 Dupixent global net sales growth below 30% year over year.
Less concerning ifQ3 Dupixent global net sales growth above 30% year over year.
Why it matters: A good decision would prove Regeneron's work in rare diseases is valuable. It would make its pipeline more trusted.
Supportive ifThe FDA will decide on garetosmab for FOP in the second half of 2026.
Worry ifThe FDA could deny or delay the decision on garetosmab past the expected date.
Why it matters: More money from collaboration shows Dupixent and other products are doing well. This helps overall growth.
Supportive ifSanofi collaboration revenue grows year over year by more than 30% in Q3 2026.
Worry ifSanofi collaboration revenue growth is less than 10% year over year in Q3 2026.
Why it matters: A drop in sector revenue growth could signal broader challenges in the healthcare market.
Worry ifSector revenue growth falls below its median rate.
Less concerning ifSector revenue growth remains above its median rate.
Why it matters: Good management of capital spending can help financial health and support growth.
Supportive ifManagement says they are keeping spending on track and within budget.
Worry ifManagement says spending is much more than they planned.
Why it matters: Approval could grow Regeneron's work in neurology. This may increase future revenue.
Supportive ifThe FDA approves cemdisiran NDA for myasthenia gravis. This will happen by Q4 2026.
Worry ifFDA rejects or delays the cemdisiran NDA beyond Q4 2026.
Why it matters: Approval could improve EYLEA's market position. This may boost sales.
Supportive ifFDA approves the EYLEA HD syringe application in Q3 2026.
Worry ifFDA rejects or delays the EYLEA HD pre-filled syringe application beyond Q3 2026.
Why it matters: A decline in gross margin could indicate rising costs or pricing pressures.
Worry ifQ3 GAAP gross margin on net product sales below 77%.
Less concerning ifQ3 GAAP gross margin on net product sales at or above 77%.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$100 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $301 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,596 loss on $10,000 · 26.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.